Addition of immunotherapy to anlotinib may prolong PFS in patients with adenocarcinoma, wild-type EGFR, stage IV disease, no liver metastasis, exsmoker status, two or more previous treatment lines, and no previous VEGF or EGFR target therapies. Here, VEGFA is linked to metastasis.